PMID- 31339604
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Print)
IS  - 1320-5358 (Linking)
VI  - 25
IP  - 7
DP  - 2020 Jul
TI  - Different type and dosage of heparin were not associated with the progression of 
      coronary artery calcification in haemodialysis patients.
PG  - 551-558
LID - 10.1111/nep.13632 [doi]
AB  - AIM: Several studies have verified that unfractionated heparin (UFH) and low 
      molecular heparin (LWMH) can induce bone loss, and bone mineral density has been 
      inversely associated with vascular calcification in some clinical researches. But 
      few have focused on the relationship between types and dosages of heparin and the 
      progression of vascular calcification. We observed the progression of coronary 
      artery calcification (CAC) in maintenance haemodialysis (MHD) patients who were 
      treated with UFH and LMWH. METHODS: This was a prospective prevalent cohort study 
      of MHD patients. Computed tomography was performed at enrolment and 2 years after 
      enrolment, and CAC score was obtained. Demographic and clinical data, baseline 
      and time-average laboratory indices were collected. Multiple linear regression 
      and logistic regression were used to estimate the influencing factors of 
      progression of CAC. RESULTS: In this study, (i) we initially enrolled 69 HD 
      patients, and then 56 patients finished the follow-up. (ii) Among the total 56 
      patients, 27 patients (48.2%) were treated with UFH, 14 (25.0%) with LMWH and 15 
      (26.8%) with both. The median baseline CAC scores of three groups (UFH, LMWH and 
      both users) were 91.0 (1.0, 1052.0), 134.0 (0, 1292.0) and 250.5 (27.0, 1139.0), 
      respectively, with no significant difference (P = 0.663); the median CAC 
      progression scores were 42.0 (0, 364.0), 172.0 (7.0, 653.0) and 118.5 (0, 434.0), 
      respectively, with no significant difference (P = 0.660). (iii) Pearson and 
      spearman correlation analysis shown that the progression of CAC was not 
      associated with cumulative dosage of heparin used. (iv) After adjusted for 
      diabetes mellitus, time-averaged intact parathyroid hormone, phosphate and 
      alkaline phosphatase, logistic regression analysis showed using different types 
      of heparin was not an independent risk factor for CAC progression; and multiple 
      linear regression analysis showed that the type of heparin used was not 
      associated with CAC progression. CONCLUSION: There were no significant 
      differences in the effects of the types and dosages of heparin on CAC progression 
      in patients on haemodialysis.
CI  - (c) 2019 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on 
      behalf of Asian Pacific Society of Nephrology.
FAU - Niu, Qingyu
AU  - Niu Q
AD  - Department of Nephrology, Peking University People's Hospital, Beijing, China.
FAU - Yang, Shuo
AU  - Yang S
AD  - Department of Nephrology, Peking University People's Hospital, Beijing, China.
FAU - Gan, Liangying
AU  - Gan L
AD  - Department of Nephrology, Peking University People's Hospital, Beijing, China.
FAU - Zhao, Huiping
AU  - Zhao H
AD  - Department of Nephrology, Peking University People's Hospital, Beijing, China.
FAU - Zuo, Li
AU  - Zuo L
AUID- ORCID: 0000-0002-7340-5995
AD  - Department of Nephrology, Peking University People's Hospital, Beijing, China.
LA  - eng
GR  - 81870524/National Natural Science foundation of China/
PT  - Journal Article
DEP - 20190829
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/administration & dosage/adverse effects
MH  - China/epidemiology
MH  - Cohort Studies
MH  - *Coronary Artery Disease/diagnosis/epidemiology
MH  - *Coronary Vessels/diagnostic imaging/pathology
MH  - Disease Progression
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - *Heparin/administration & dosage/adverse effects
MH  - *Heparin, Low-Molecular-Weight/administration & dosage/adverse effects
MH  - Humans
MH  - *Kidney Failure, Chronic/epidemiology/therapy
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Prospective Studies
MH  - Renal Dialysis/adverse effects/methods
MH  - Risk Assessment
MH  - *Vascular Calcification/diagnosis/etiology
PMC - PMC7317585
OTO - NOTNLM
OT  - chronic kidney disease-mineral and bone disorder
OT  - haemodialysis
OT  - heparin
OT  - low-molecular-weight
OT  - vascular calcification
EDAT- 2019/07/25 06:00
MHDA- 2021/03/30 06:00
PMCR- 2020/06/26
CRDT- 2019/07/25 06:00
PHST- 2019/06/30 00:00 [accepted]
PHST- 2019/07/25 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2019/07/25 06:00 [entrez]
PHST- 2020/06/26 00:00 [pmc-release]
AID - NEP13632 [pii]
AID - 10.1111/nep.13632 [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2020 Jul;25(7):551-558. doi: 10.1111/nep.13632. Epub 2019 
      Aug 29.